SCHEMBL3086202

SCHEMBL3086202

CCN(CC)C(=O)C(Cc1ccc(NC(=O)c2ccccc2Cl)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMO Q99835 2/20 0.46
KMT2A Q03164 3/20 0.44
TP53 P04637 3/20 0.44
POLB P06746 2/20 0.44
LARS1 Q9P2J5 1/20 0.43
GPR27 Q9NS67 1/20 0.42
ALDH1A1 P00352 3/20 0.42
LMNA P02545 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PCTP Q9UKL6 1/20 0.42
MAPT P10636 4/20 0.41
MEN1 O00255 2/20 0.41
GAA P10253 2/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
F2 P00734 1/20 0.41
KAT6A Q92794 1/20 0.41
PABPC1 P11940 1/20 0.41
ITGB1 P05556 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3092326 0.93 F2 (0.42) SMOKMT2ATP53POLBLARS1
SCHEMBL3093284 0.90 KAT6A (0.49) KMT2ALARS1ALDH1A1SMN1; SMN2MAPT
SCHEMBL3093039 0.90 MEN1 (0.50) KMT2ATP53LARS1ALDH1A1LMNA
SCHEMBL3089252 0.90 NR1H4 (0.43) KMT2APOLBLARS1ALDH1A1LMNA
SCHEMBL3100518 0.90 NPC1 (0.51) KMT2ATP53POLBLARS1LMNA
SCHEMBL3096503 0.90 LARS1 (0.45) KMT2ALARS1ALDH1A1MAPTMEN1
SCHEMBL15000205 0.90 MEN1 (0.46) KMT2ALARS1ALDH1A1MAPTMEN1
SCHEMBL3096098 0.90 LARS1 (0.45) KMT2ALARS1ALDH1A1MAPTMEN1
SCHEMBL3101165 0.90 NPC1 (0.51) KMT2ATP53POLBLARS1LMNA
SCHEMBL3090331 0.89 LARS1 (0.47) KMT2APOLBLARS1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 SMO 1817/4885KMT2A 1948/4885TP53 3377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.